|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Herve Hoppenot||CEO & Chairman||2,89M||N/D||1960|
|Ms. Christiana Stamoulis MBA||Exec. VP & CFO||1,16M||N/D||1971|
|Ms. Maria E. Pasquale J.D.||Exec. VP, Gen. Counsel & Corp. Sec.||1,02M||N/D||1966|
|Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.||Exec. VP & GM of North America||996,28k||545,65k||1958|
|Dr. Steven H. Stein M.D.||Exec. VP & Chief Medical Officer||1,22M||N/D||1967|
|Dr. Pablo J. Cagnoni M.D., Ph.D.||Pres and Head of R&D||N/D||N/D||1963|
|Mr. Thomas Tray||VP of Fin., Chief Accounting Officer & Controller||N/D||N/D||1978|
|Mr. Michael James Morrissey||Exec. VP & Head of Global Technical Operations||N/D||N/D||1964|
|Ms. Christine Chiou||Head of Investor Relations||N/D||N/D||N/D|
|Ms. Pamela M. Murphy||VP of Investor Relations & Corp. Communications||N/D||N/D||1951|
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
L'ISS Governance QualityScore di Incyte Corporation al 1 settembre 2023 è 8. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 6; diritti degli azionisti: 6; retribuzione: 9.